Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Shares Outstanding data on record, last reported at $74.7 million in Q3 2025.

  • For Q3 2025, Shares Outstanding rose 19.34% year-over-year to $74.7 million; the TTM value through Sep 2025 reached $74.7 million, up 19.34%, while the annual FY2024 figure was $67.9 million, 38.46% up from the prior year.
  • Shares Outstanding reached $74.7 million in Q3 2025 per CRVS's latest filing, roughly flat from $74.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $74.7 million in Q3 2025 and bottomed at $46.6 million in Q1 2022.
  • Average Shares Outstanding over 4 years is $55.9 million, with a median of $49.0 million recorded in 2023.
  • The widest YoY moves for Shares Outstanding: up 608.62% in 2023, down 0.03% in 2023.
  • A 4-year view of Shares Outstanding shows it stood at $46.6 million in 2022, then rose by 5.34% to $49.0 million in 2023, then skyrocketed by 38.46% to $67.9 million in 2024, then rose by 9.99% to $74.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $74.7 million in Q3 2025, $74.5 million in Q2 2025, and $68.2 million in Q1 2025.